Novavax Inc Stock Price, News & Analysis

Novavax (NASDAQ: NVAX) announced the appointment of Ben Machielse as Executive Vice President, CMC, on June 29, 2020. Machielse will oversee manufacturing and regulatory functions as the company advances its COVID-19 vaccine candidate, NVX-CoV2373. Other leadership promotions include John Trizzino as Chief Business Officer and CFO, John Herrmann III as Chief Legal Officer, and Jill Hoyt as Chief Human Resources Officer. Novavax is ramping up its manufacturing capacity for its vaccines, which include NVX-CoV2373 and NanoFlu, with clinical trial results expected soon.

Novavax, a biotechnology company focused on vaccines, will have its Chief Business Officer, John J. Trizzino, participate in the H.C. Wainwright Virtual Fireside Chat on June 25, 2020, at 10:00 a.m. ET. The discussion will center on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This candidate is part of Novavax's broader mission to develop innovative vaccines, including the NanoFlu™, which recently succeeded in a Phase 3 trial. More insights can be found on Novavax's website.

Novavax, Inc. (NASDAQ: NVAX) has appointed David Mott as an independent director of its Board, enhancing its leadership team with his extensive experience in biopharmaceuticals. Mott, who recently acquired nearly 65,000 shares of Novavax, brings over 30 years of management and investment expertise. His appointment comes as Novavax ramps up efforts in developing its COVID-19 vaccine (NVX-CoV2373) and prepares for regulatory submissions for NanoFlu™. Mott will also serve on the Compensation Committee, aiming to support the company's mission against serious infectious diseases.

Novavax (NASDAQ: NVAX) announced a private placement agreement to sell Series A Convertible preferred stock to RA Capital Management, converting into 4,388,852 shares of common stock at the June 12 closing price. The deal will provide Novavax with gross proceeds of approximately $200 million. This funding is expected to bolster Novavax's ongoing vaccine development efforts against COVID-19 and influenza. The preferred shares do not have voting rights and are not entitled to dividends. The transaction is part of Novavax's strategy to enhance its financial position and facilitate critical vaccine trials.

Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D., President of Research and Development, will participate in a panel discussion on COVID-19 vaccines at the 2020 BIO Digital conference on June 9 at 11:30 a.m. EDT. The panel will explore the complexities of vaccine development and the importance of collaboration in bringing vaccines to market. Additionally, Novavax is advancing its NVX-CoV2373 vaccine candidate for COVID-19 with Phase 1 results expected in July 2020, alongside positive Phase 3 results for its NanoFlu vaccine targeting influenza.

Novavax, Inc. (NASDAQ: NVAX) announced a $60 million contract with the U.S. Department of Defense (DoD) to manufacture its COVID-19 vaccine candidate, NVX-CoV2373. The funding will support the production of components required to deliver 10 million doses by the end of 2020. This contract aims to enhance Novavax's U.S. production capacity, facilitating support for the COVID-19 pandemic. The vaccine, incorporating proprietary technologies, shows promise in preclinical trials for generating antibodies to combat the virus.

Novavax (NASDAQ: NVAX) announced the enrollment of the first participants in the Phase 1/2 clinical trial for its coronavirus vaccine, NVX-CoV2373. This vaccine utilizes proprietary nanoparticle technology and Matrix-M™ adjuvant to boost immune response. Preliminary results on immunogenicity and safety are anticipated in July 2020, with the Phase 2 trial set to follow if Phase 1 results are promising. The trial is supported by funding from CEPI, highlighting Novavax's commitment to combating COVID-19.

Novavax (NASDAQ: NVAX) has secured up to $384 million in additional funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the clinical development of its coronavirus vaccine, NVX-CoV2373. This funding enhances the rapid scale-up of vaccine manufacturing and the production of Matrix-M™ adjuvant, aiming to significantly boost global vaccine supply. Key plans include initiating a Phase 1/2 clinical trial in Australia and potentially manufacturing over one billion vaccine doses in 2021, highlighting a strong commitment to global equitable access.

Novavax (Nasdaq: NVAX) announced that Dr. Gregory Glenn will present updates on NVX-CoV2373, its coronavirus vaccine candidate, during a COVID-19 webinar on May 13, 2020. This informative session is part of the World Vaccine Congress and aims to address ongoing global vaccine development efforts. NVX-CoV2373, engineered from the SARS-CoV-2 sequence, uses recombinant nanoparticle technology to generate effective immune responses. A Phase 1 clinical trial is set to begin in May 2020, with initial results expected by July. CEPI has provided $4 million to support this initiative.